COV · Covalon Technologies Ltd. · Investor Relations

Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, has announced that the Company has granted an aggregate of 97,674 Deferred Share Units (“DSUs”) to four of its non-employee directors that elected to receive all or a portion of their annual directors’ fees for fiscal year 2026 in DSUs as opposed to cash. The DSUs were granted under the Company's Amended and Restated Omnibus Long-Term Incentive Plan adopted effective on March 25, 2026. The DSUs will vest 12 months from the date of grant. The deemed value for the DSUs was calculated using the last closing price of the Company’s common shares on the TSX Venture Exchange prior to the date of grant, being $1.72 multiplied by the number of DSUs awarded. Those interested in learning more about Covalon can visit www.covalon.com or follow Covalon on LinkedIn , Facebook , Instagram , or X . About Covalon Covalon is a leading MedTech company dedicated to improving patient

Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced the results of the matters voted upon at its fiscal 2025 Annual General and Special Meeting of Shareholders (the "Meeting") held on March 25, 2026. Shareholders voted in favour of all items of business at the Meeting and each item of business was approved by the requisite number of votes. The approved matters included (i) the election of the Board of Directors, (ii) the appointment of PricewaterhouseCoopers LLP as auditors, (iii) an amendment to the Company's articles to permit the Company to create and issue classes of preferred shares and add such preferred shares to the authorized capital of the Company, (iv) the Company's amended and restated by-law no. 1 and repeal of by-law no. 2, (v) the new advance notice by-law, (vi) the Company's amended and restated long-term omnibus incentive plan, and (vii) options granted to Ms. Crooks, the Company's

Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, has announced that the annual meeting of shareholders of the Company will be held on Wednesday, March 25, 2026 at 2:00pm Eastern Time in a virtual-only format where shareholders may attend and participate in the meeting via live webcast. The meeting will include a presentation from Covalon’s CEO, Brent Ashton, with a Question and Answer session to follow. Registered shareholders and duly appointed proxyholders will be able to attend, participate, and vote at the Meeting online at https://virtual-meetings.tsxtrust.com/en/1871 , Meeting ID being 1871, using Password “covalon2026” (case sensitive). If you are a registered shareholder and you want to appoint someone else (other than the Management nominees) to vote online at the Meeting, you must first submit your proxy indicating who you are appointing. You or your appointee must then register with TSX Trust in

Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its fiscal 2026 first quarter results for the period ended December 31, 2025, along with its recent achievements and highlights. Full financial statements and management discussion and analysis are available on the Company’s profile at www.sedarplus.ca . Brent Ashton, Covalon’s Chief Executive Officer’s commented, “Covalon’s first quarter of fiscal 2026 delivered results just above a breakeven, reflecting normal quarter-to-quarter variability in the timing of orders received and shipments fulfilled. Notably, sales and orders received in the first half of the second quarter, from January 1 to February 15, 2026 have already exceeded the total revenue reported for Q1 fiscal 2026. As a result, we are confident that we will remain on track for a strong Q2 and a strong fiscal 2026 overall. Covalon’s recent clinical validations, accelerating sales wins

Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company focused on improving patient safety and clinical outcomes, today announced an upcoming Continuing Education webinar to be presented by internationally recognized vascular access expert Dr. Nancy Moureau and hosted by the distinguished Association for Vascular Access (AVA), a leading global authority on vascular access. The webinar will focus on the persistent clinical challenge of IV line contamination and its contribution to Catheter-Associated Blood Stream Infection (CABSI) risk - an important patient safety issue across care settings. “Life-threatening complications stemming from IV line contamination are not inevitable, they are preventable,” said Dr. Nancy Moureau, PhD, RN, CRNI, CPUI, VA-BC. “When we address contamination at its source, we directly strengthen patient safety. This session challenges clinicians to examine and refine the everyday practices that

Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, will release its Q1 Fiscal 2026 results on Wednesday, February 25, 2026, before markets open. A conference call and webcast to discuss the results will be held on Wednesday, February 25, 2026, at 8:30am ET. To view, listen to, and participate in the live webcast, please follow the link below: https://events.q4inc.com/attendee/620262525 To listen and participate via the conference call, please dial: North American Toll-Free: 1-800-549-8228 Local (Toronto): 289-819-1520 Local (New York): 646-564-2877 Conference ID: 56849 Participants will be able to ask questions during the Q&A portion of the conference call either by asking them on the call or by submitting them using the chat function on the webcast. A recording of the call will be available on www.covalon.com under News & Events on the Investors tab. Copies of Covalon’s financial